文献速递药物相互作用

利用真实世界理赔数据评估目标患者人群中合并用药的DDI风险

Use of Real-World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug-Drug Interaction Risk in Target Patient Populations.
PubMed 文献 · Clin Pharmacol Ther · 2025-04-01

该文探讨利用美国大型封闭理赔数据库IQVIA PharMetrics® Plus表征目标适应证中与DDI相关的合并用药使用情况,并以多发性硬化症和激素受体阳性乳腺癌为例,识别出他汀类(阿托伐他汀和辛伐他汀,CYP3A4底物)的普遍且长期使用,提示潜在DDI风险,可辅助临床药物研发决策。

要点

  • 理赔数据库可表征目标人群中与DDI相关的合并用药使用。
  • 多发性硬化症和激素受体阳性乳腺癌患者中普遍长期使用他汀类。
  • 阿托伐他汀和辛伐他汀为CYP3A4底物,提示潜在DDI风险。

核心结论

  • 真实世界理赔数据可用于了解目标适应证中合并用药使用,以评估潜在DDI风险并辅助临床药物研发决策。

研究设计与样本

  • 描述性研究,使用美国大型封闭理赔数据库IQVIA PharMetrics® Plus,以多发性硬化症和激素受体阳性乳腺癌为两个案例表征DDI相关合并用药使用。

主要发现

  • 在多发性硬化症和激素受体阳性乳腺癌两个疾病案例中均识别出他汀类(阿托伐他汀和辛伐他汀,CYP3A4底物)的普遍且长期使用。

临床怎么用

  • 在临床药物研发中,可利用理赔数据库了解目标患者人群的合并用药模式,以辅助DDI风险评估和决策。

局限性

  • 原文讨论了局限性,但摘要未提供具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A common issue in clinical drug development involves drug-drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population. The drug development pipeline therefore involves DDI risk assessment of the investigational drug based on in vitro studies, in silico modeling, and clinical trials. Real-world data (RWD), particularly claims databases with reliable information on pharmacy dispensing, provide an opportunity to understand conmeds usage in the target indication in a real-world setting as one approach to assess potential DDI risk. We describe two cases of characterizing DDI-related conmeds usage with a large closed US-based claims database, IQVIA PharMetrics® Plus, and identified potential DDI risk for multiple sclerosis and hormone receptor-positive breast cancer. For example, prevalent and chronic use of statins (atorvastatin and simvastatin), which are CYP3A4 substrates, were identified among both disease cases. Further examples, limitations, and future directions are also discussed. These insights can therefore help augment decision-making during clinical drug research and development.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tang AS, Brooks L, Boudreau DM, et al. Use of Real-World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug-Drug Interaction Risk in Target Patient Populations. Clin Pharmacol Ther. 2025. PMID: 40170515. doi:10.1002/cpt.3652

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。